News

Vedanta has best dividend yield among large-cap stocks Vedanta Ltd has the best dividend yield in the last 12 months among large-cap stocks at 31 per cent. As per a report by Axis Securities, it is followed by Hindustan Zinc at 25 per cent, Coal India at 10 per cent, ONGC at 8 per cent, and Power Grid and GAIL at 5 per cent. Among the mid-cap companies, Sanofi India, REC and Oil India have the best dividend yield at 8 per cent, followed by Power Finance Corporation and Oracle Financial Services at 6 per cent. Among the small-cap companie...
Vedanta has best dividend yield among large-cap stocks
Vedanta has best dividend yield among large-cap stocks
Source: IANS
17/07/2023 5:28:50 PM
Sanofi India shines on getting nod to demerge consumer healthcare business into separate entity Sanofi India is currently trading at Rs. 6117.00, up by 418.40 points or 7.34% from its previous closing of Rs. 5698.60 on the BSE. The scrip opened at Rs. 5770.00 and has touched a high and low of Rs. 6160.00 and Rs. 5754.25 respectively. So far 9102 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 7020.00 on 01-Jun-2022 and a 52 week low of Rs. 5240.00 on 08-Feb-2023. Last one week high and low of the scrip st...
Sanofi India shines on getting nod to demerge consumer healthcare business into separate entity
Sanofi India shines on getting nod to demerge consumer healthcare business into separate entity
Source: Accord Fintech
11/05/2023 12:53:28 PM
Hold Sanofi India Ltd For Target Rs.6270 - ICICI Direct Weak Q4; power brands growth, future divestitures to be keenly watched… About the stock: Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, pain, allergy and epilepsy * Around 70% of sales stem from top seven brands. Lantus, Allegra & Combiflam are in top 100 pharmaceutical brands in India * Sanofi enjoys strong brand recall in anti-diabetic therapy in India   Q4CY22 Results: Sanofi India reported weak numbers in-line with our exp...
Hold Sanofi India Ltd For Target Rs.6270 - ICICI Direct
Hold Sanofi India Ltd For Target Rs.6270 - ICICI Direct
Source: ICICI Direct Ltd
1/03/2023 11:44:33 AM
Buy Sanofi India Ltd For Target Rs.6,580 - Centrum Broking Strong earnings; NLEM uncertainties over Sanofi’s Q4CY22 revenue and PAT came above our estimates. Revenue at Rs5.8bn declined by 2% YoY and 3% QoQ, due to the divestment of Universal Medicare business and two brands Soframycin + Sofradex (part of base biz till last year). Gross margin improvement by ~300bps YoY mainly driven by a favorable mix at 58.2%. EBITDA margin improved by 635bps on YoY at 24.8% on lower overheads cost. Furthermore, the adjusted PAT increased by 29% YoY to Rs1...
Buy Sanofi India Ltd For Target Rs.6,580 - Centrum Broking
Buy Sanofi India Ltd For Target Rs.6,580 - Centrum Broking
Source: Centrum Broking Ltd
28/02/2023 3:06:50 PM
Hold Sanofi India Ltd For Target Of Rs. 6885 - ICICI Securities Q2 muted on high base of Covid and divestments… About the stock: Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, pain, allergy and epilepsy. * Around 70% of sales stem from top 7 brands. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India * Sanofi enjoys strong brand recall in anti-diabetic therapy in India Q2CY22 Results: Sanofi India reported muted numbers this quarter amid divested business and Covid sales in b...
Hold Sanofi India Ltd For Target Of Rs. 6885 - ICICI Securities
Hold Sanofi India Ltd For Target Of Rs. 6885 - ICICI Securities
Source: ICICI Securities Ltd
7/10/2022 2:03:58 PM
Add Sanofi India Ltd For Target Rs 7,072 - ICICI Securities High costs suppress margins Sanofi India’s (SANL) Q2CY22 performance was below our estimates on the profitability front. Revenues declined 11.4% YoY to Rs7.0bn (I-Sec: Rs.7.1bn) due to divestment of the nutraceutical business and brands. EBITDA margin contracted 830bps YoY and 450bps QoQ to 23% (I-Sec: 26.5%) due to negative operating leverage and fixed costs amidst lower revenues. In the past few years, the company’s growth and profitability were fuelled by power brands. We re...
Add Sanofi India Ltd For Target Rs 7,072 - ICICI Securities
Add Sanofi India Ltd For Target Rs 7,072 - ICICI Securities
Source: ICICI Securities Ltd
24/09/2022 11:07:46 AM
Buy Sanofi India Ltd For Target Rs.8,500 - Centrum Broking Below estimates; focus remain on power brands   Sanofi India’s  results  for  2QCY22  (below  our  estimates)  with  revenues  declining  by 9.6% YoY and flat QoQ to Rs 6.1 bn and PAT de?grew by 32.5% YoY and flat QoQ to Rs  1.2 bn (EPS of Rs 52.3 per share). Higher RMC impacted gross margins contraction by  236bps  YoY  and  330bps QoQ  to  54.3%  and &nb...
Buy Sanofi India Ltd For Target Rs.8,500 - Centrum Broking
Buy Sanofi India Ltd For Target Rs.8,500 - Centrum Broking
Source: Centrum Broking Ltd
28/07/2022 12:42:05 PM
Sanofi India Q2 net profit down 32.47% at Rs 120.40 cr The company reported standalone net profit of Rs 120.40 crore for the quarter ended June 30, 2022 as compared to Rs 178.30 crore in the same period last year, registering a year-on-year decline of 32.47 per cent. Net revenue of the company declined moderately by 11.38 per cent at Rs 699.30 crore in April-June quarter of this fiscal as against Rs 789.10 crore in the corresponding period last year. During April-June quarter, operating expenses dropped by 0.70 per cent to Rs 538.20 crore from...
Sanofi India Q2 net profit down 32.47% at Rs 120.40 cr
Sanofi India Q2 net profit down 32.47% at Rs 120.40 cr
Source: Dion Global Solutions Ltd
27/07/2022 10:32:43 AM
ADD Sanofi India Ltd Ltd For Target Rs.7,955 - ICICI Securities Curtailed expenses lift margins Sanofi India’s (SANL) Q1CY22 performance was above our expectations across parameters. While revenue declined 2.5% YoY due to the divestment of nutraceutical business and brands, it grew 2.8% QoQ to Rs7.1bn (I-Sec: Rs6.7bn). EBITDA margin expanded 140bps YoY and 900bps QoQ to 27.5% aided by inventory adjustments (I-Sec: 20.8%). Adjusted PAT grew 4.2% YoY to Rs1.5bn. SANL announced a dividend of Rs490/share post recent sale of assets. In the past few ye...
ADD Sanofi India Ltd Ltd For Target Rs.7,955 - ICICI Securities
ADD Sanofi India Ltd Ltd For Target Rs.7,955 - ICICI Securities
Source: ICICI Securities Ltd
28/04/2022 12:14:04 PM
Sanofi India Q1 net profit jumps 63.40% at Rs 238.40 cr The company reported standalone net profit of Rs 238.40 crore for the quarter ended March 31, 2022 as compared to Rs 145.90 crore in the same period last year, registering a year-on-year growth of 63.40 per cent. Net revenue of the company declined marginally by 2.50 per cent at Rs 707.00 crore in January-March quarter of this fiscal as against Rs 725.10 crore in the corresponding period last year. During January-March quarter, operating expenses dropped by 4.33 per cent to Rs 512.50 crore...
Sanofi India Q1 net profit jumps 63.40% at Rs 238.40 cr
Sanofi India Q1 net profit jumps 63.40% at Rs 238.40 cr
Source: Dion Global Solutions Ltd
26/04/2022 5:03:03 PM
Add Sanofi India Ltd For Target Rs.8,107 - ICICI Securities Brand divestment impacts performance Sanofi India’s (SANL) Q4CY21 performance was below our expectation on all fronts, partially due to the divestment of Soframycin and Sofradex assets. Revenue declined 4.5% YoY and 8.8% QoQ to Rs6.9bn (I-Sec: Rs7.5bn). EBITDA margin shrank 470bps YoY and 790bps QoQ to 18.5% (I-Sec: 25.3%). Adjusted PAT declined 23.0% YoY to Rs904mn. SANL announced a dividend of Rs490/share. Barring quarter volatility, in the past few years, the company’s growt...
Add Sanofi India Ltd For Target Rs.8,107 - ICICI Securities
Add Sanofi India Ltd For Target Rs.8,107 - ICICI Securities
Source: ICICI Securities Ltd
12/03/2022 1:20:14 PM
Add Sanofi India Ltd For Target Rs.8,107 - ICICI Securities Sanofi Q4CY21 concall highlights Sanofi India Limited (SANL) hosted an investor call to discuss the results for Q4CY21 and CY21. We have summarised the highlights below: * Excluding the divestment of nutraceutical brands, like-to-like domestic sales growth in CY21 was ~13%; excluding COVID-19 impact, growth was in line with the domestic market. * Sequential 8.8% decline in sales was due to divestment of nutraceutical brands (~5% of domestic sales) and higher demand of Clexane in...
Add Sanofi India Ltd For Target Rs.8,107 - ICICI Securities
Add Sanofi India Ltd For Target Rs.8,107 - ICICI Securities
Source: ICICI Securities Ltd
5/03/2022 11:17:10 AM
Buy Sanofi India Ltd For Target Rs.8965 - ICICI Direct Domestic business (ex-divestment) grows at 13% in CY21 About the stock: Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, thrombosis, anti-infective, CNS, allergy, vitamins, minerals & supplements. * Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India * Sanofi is one of the fastest growing companies in India in anti-diabetic therapy   Q4CY21 Results: Sanofi India reported muted numbers this quarter. However, do...
Buy Sanofi India Ltd For Target Rs.8965 - ICICI Direct
Buy Sanofi India Ltd For Target Rs.8965 - ICICI Direct
Source: ICICI Direct
1/03/2022 10:05:59 AM
Sanofi India trades higher despite reporting 27% fall in December quarter net profit Sanofi India is currently trading at Rs. 7295.00, up by 17.55 points or 0.24% from its previous closing of Rs. 7277.45 on the BSE. The scrip opened at Rs. 7276.00 and has touched a high and low of Rs. 7369.00 and Rs. 7176.00 respectively. So far 1412 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 9300.00 on 10-Aug-2021 and a 52 week low of Rs. 6949.35 on 27-Jan-2022. Last one week high and low of the scrip sto...
Sanofi India trades higher despite reporting 27% fall in December quarter net profit
Sanofi India trades higher despite reporting 27% fall in December quarter net profit
Source: Accord Fintech
24/02/2022 12:32:22 PM
Add Sanofi India Ltd For Target Rs.8,774 - ICICI Securities Divestment of Nutraceuticals complete Rs8,069 Sanofi India’s (SANL) Q3CY21’s performance was below estimates, however, adjusting for the divestment of nutraceutical division, it was broadly in line. Revenue grew 9.9% YoY to Rs7.5bn (I-Sec: Rs8.1bn). EBITDA margin dropped 170bps YoY and 500bps QoQ to 26.3% (I-Sec: 28.5%). Adjusted PAT grew 15.0% to Rs1.5bn. SANL recorded an exceptional income of Rs4.9bn from the sale of nutraceutical division. In the past few years, the company&...
Add Sanofi India Ltd For Target Rs.8,774 - ICICI Securities
Add Sanofi India Ltd For Target Rs.8,774 - ICICI Securities
Source: ICICI Securities
23/11/2021 9:42:44 AM
Add Sanofi India Ltd For Target Rs.8,989 - ICICI Securities Another quarter of controlled costs Sanofi India’s (SANL) Q2CY21’s performance was yet again supported by controlled costs. Revenue grew 11.1% YoY to Rs7.9bn but it was below our estimate of Rs8.2bn. EBITDA margin improved 640bps YoY and 520bps QoQ with lower expenses to 31.3%. Adjusted PAT grew 31.6% to Rs1.8bn. As per AIOCD data, company reported a YoY growth of 30.8% for the quarter. In the past few years, the company’s growth and profitability was fuelled by the po...
Add Sanofi India Ltd For Target Rs.8,989 - ICICI Securities
Add Sanofi India Ltd For Target Rs.8,989 - ICICI Securities
Source: ICICI Securities
30/08/2021 11:01:19 AM
Buy Sanofi India Ltd For Target Rs. 9,750 - ICICI Direct Decent performance with strong margins… About the stock: Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, thrombosis, anti-infective, CNS, allergy, vitamins, minerals & supplements. * Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India * Sanofi is one of the fastest growing companies in India in anti-diabetic therapy   Q2CY21 Results: Sanofi India reported robust Q2CY21 results. * Sales were ...
Buy Sanofi India Ltd For Target Rs. 9,750 - ICICI Direct
Buy Sanofi India Ltd For Target Rs. 9,750 - ICICI Direct
Source: ICICI Direct
9/08/2021 9:33:15 AM
Add Sanofi India Ltd For Target Of Rs. 8,570 - ICICI Securities Controlled costs boosts margin Sanofi India’s (SANL) Q1CY21 performance was supported by controlled costs. Revenue declined 7.6% YoY to Rs7.3bn but sequentially it remained stable. EBITDA margin improved 360bps YoY and 290bps QoQ with lower expenses to 26.1%. Adjusted PAT grew 24.3% to Rs1.5bn. As per AIOCD data, company reported a YoY growth of 2.9% for the quarter. In the past few years, the company’s growth and profitability was fuelled by the power brands. We remain positiv...
Add Sanofi India Ltd For Target Of Rs. 8,570 - ICICI Securities
Add Sanofi India Ltd For Target Of Rs. 8,570 - ICICI Securities
Source: ICICI Securities Ltd
4/05/2021 11:19:06 AM
Add Sanofi India Ltd For Target Rs.8,633 - ICICI Securities Analyst call highlights Sanofi India Limited’s (SANL) is poised to grow owing to its high chronic exposure in the domestic market supported by strong balance sheet with deep cash reserves, and strong brand equity built over the years. We cover the highlights from its virtual investor meet below: * Company believes that its performance has been resilient during the past few months as it was not materially affected by any breakdown of logistics or shortage of raw materials as well ...
Add Sanofi India Ltd For Target Rs.8,633 - ICICI Securities
Add Sanofi India Ltd For Target Rs.8,633 - ICICI Securities
Source: ICICI Securities Ltd
23/03/2021 10:57:01 AM
Buy Sanofi India Ltd For Target Rs.9820 - ICICI Direct Divestiture, Covid-19 impact sales; margins upbeat… CY20 revenues de-grew 5.5% YoY to | 2902 crore mainly due to divestiture of few products to Zentiva (Ankaleshwar slump sale) and Covid-19 impact on certain therapies. EBITDA margins improved 291 bps YoY to 24.6% mainly due to lower other expenditure and slightly better gross margins. Subsequently, EBITDA grew 7.2% YoY to | 713 crore. Adjusted PAT grew 9.7% YoY to | 519 crore. Note: Results are not comparable YoY due to closure of t...
Buy Sanofi India Ltd For Target Rs.9820 - ICICI Direct
Buy Sanofi India Ltd For Target Rs.9820 - ICICI Direct
Source: ICICI Direct
11/03/2021 11:17:53 AM
Add Sanofi India Ltd For Target Rs.8,594 - ICICI Securities Weak quarter; sequential improvement Sanofi India’s (SANL) Q4CY20’s performance remained weak during the quarter. Revenue declined 12.8% YoY to Rs7.2bn but sequentially improved by 4.9%. EBITDA margin improved 160bps YoY with lower expenses but declined by 480bps QoQ to 23.2%. Adjusted PAT grew 7.4% to Rs1.2bn. As per AIOCD data, company reported a YoY growth of 3.8% for the quarter. In the past few years, the company’s growth and profitability was fuelled by the power b...
Add Sanofi India Ltd For Target Rs.8,594 - ICICI Securities
Add Sanofi India Ltd For Target Rs.8,594 - ICICI Securities
Source: ICICI Securities Ltd
1/03/2021 10:56:46 AM
Sanofi India Q4 net profit up 26.41% at Rs 123.00 cr The company reported standalone net profit of Rs 123.00 crore for the quarter ended December 31, 2020 as compared to Rs 97.30 crore in the same period last year, registering a year-on-year growth of 26.41 per cent. Net revenue of the company declined moderately by 12.83 per cent at Rs 720.30 crore in October-December quarter of this fiscal as against Rs 826.30 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 14.63 per cent...
Sanofi India Q4 net profit up 26.41% at Rs 123.00 cr
Sanofi India Q4 net profit up 26.41% at Rs 123.00 cr
Source: Dion Global Solutions Ltd
24/02/2021 11:33:27 AM
Buy Sanofi India Ltd For Target Rs.9,460 - HDFC Securities Buy Sanofi India Ltd For Target Rs.9,460 - HDFC Securities Our Take: Sanofi India (Sanofi), is the Indian subsidiary of France- based pharma multinational Sanofi SA. After the divestment of Ankleshwar facility to Zentiva, the contribution from domestic business would increase from H2CY20 onwards. It derived ~70% of its revenues from India (market share of ~2%) and the balance from exports (largely Europe, Australia and Russia). Sanofi is a chronic focused player with a presence...
Buy Sanofi India Ltd For Target Rs.9,460 - HDFC Securities
Buy Sanofi India Ltd For Target Rs.9,460 - HDFC Securities
Source: HDFC Securities Ltd
11/01/2021 12:55:10 PM